|
|
| Zeile 32: |
Zeile 32: |
| </DPL> | | </DPL> |
| </td></tr></table> | | </td></tr></table> |
|
| |
|
| |
| ==Abkürzungen aus der A630==
| |
| ;[[26. BImSchV]]
| |
| : {{#lst:26. BImSchV|abk}}
| |
| ; AGNIR
| |
| : <u>A</u>dvisory <u>G</u>roup on <u>N</u>on-<u>I</u>onising <u>R</u>adiation (Großbritannien)
| |
| ;[[ANSES]]
| |
| : {{#lst:ANSES|abk}}
| |
| ;[[ARPANSA]]
| |
| : {{#lst:ARPANSA|abk}}
| |
| ;[[BAFU]]
| |
| : {{#lst:BAFU|abk}}
| |
| ;ETSI
| |
| : <u>E</u>uropean <u>T</u>elecommunications <u>S</u>tandards <u>I</u>nstitute
| |
| ;INTEROCC
| |
| :Studienakronym: Occupational Exposures And Brain Cancer
| |
| ;Sham
| |
| : Scheinexposition
| |
| ;SMM
| |
| : <u>S</u>moldering <u>M</u>ultiples <u>M</u>yelom
| |
|
| |
| ==Begriffe aus der A229==
| |
| <table>
| |
| <tr><th colspan="3"> </th></tr>
| |
| <tr><td>
| |
| <DPL>
| |
| uses=Template:Nuklide Nuklearmedizin
| |
| category = Ungeprüft
| |
| ordermethod=title
| |
| count=65
| |
| </DPL>
| |
| </td>
| |
| </tr></table>
| |
|
| |
| ==Abkürzungen aus der A229==
| |
| ;ALSYMPCA-Studie
| |
| : <u>A</u>lpharadin in <u>sym</u>ptomatic <u>p</u>rostate <u>c</u>ancer -Studie
| |
| ;[[AMG]]
| |
| : {{#lst:AMG|abk}}
| |
| ;[[BfS]]
| |
| : {{#lst:BfS|abk}}
| |
| ;[[BMU]]
| |
| : {{#lst:BMU|abk}}
| |
| ;CUP
| |
| : <u>C</u>ancer of <u>u</u>nknown <u>p</u>rimary origin (''Krebserkrankung mit unbekanntem Primärtumor'')
| |
| ;CXCR4
| |
| : <u>CXC</u>-Motiv-Chemokin<u>r</u>ezeptor <u>4</u>
| |
| ;DOTANOC
| |
| : [DOTA,1-Nal3]-octreotide
| |
| ;DOTATE
| |
| : DOTA-(Tyr3)-octreotate
| |
| ;DOTATOC
| |
| :DOTA(0)-Phe(1)-Tyr(3))octreotide, Edotreotid
| |
| ;DTC
| |
| : <u>D</u>ifferentiated <u>t</u>hyroid <u>c</u>arcinoma (''differenziertes Schilddrüsenkarzinom'')
| |
| ;[[ECOG]]
| |
| : {{#lst:ECOG|abk}}
| |
| ;EDTMP
| |
| : <u>E</u>thylene<u>d</u>iamine <u>t</u>etra(<u>m</u>ethylene <u>p</u>hosphonic acid) (''Ethylendiamintetra(methylphosphorsäure'')
| |
| ;GEP-NET
| |
| : <u>G</u>astro<u>e</u>ntero<u>p</u>ankreatisch <u>N</u>euroendokrine <u>T</u>umoren
| |
| ;GFR
| |
| : <u>G</u>lomeruläre <u>F</u>iltrations<u>r</u>ate
| |
| ;LHRH
| |
| : <u>L</u>uteinisierendes-<u>H</u>ormon-<u>R</u>eleasing-<u>H</u>ormon
| |
| ;mCRPC
| |
| : <u>m</u>etastatic <u>c</u>astration-<u>r</u>esistant <u>p</u>rostate <u>c</u>ancer (''metastasierten kastrationsresistenten Prostatakarzinom'')
| |
| ;MDS
| |
| : <u>M</u>yelo<u>d</u>ysplastische <u>S</u>yndrome
| |
| ;NET
| |
| : <u>N</u>euro<u>e</u>ndokriner <u>T</u>umor
| |
| ;NSz
| |
| : <u>N</u>ieren<u>sz</u>intigraphie
| |
| ;NYHA
| |
| : <u>N</u>ew <u>Y</u>ork <u>H</u>ealth <u>A</u>ssociation
| |
| ;PDTC
| |
| : <u>P</u>oorly <u>d</u>ifferentiated <u>t</u>hyroid <u>c</u>arcinoma (''schlecht differenziertes Schilddrüsenkarzinom'')
| |
| ;[[PET (-Studie)|PET]]
| |
| : {{#lst:PET (-Studie)|abk}}
| |
| ;PRRT
| |
| : <u>P</u>eptid-<u>R</u>adio-<u>R</u>ezeptor-<u>T</u>herapie
| |
| ;PSMA
| |
| : <u>P</u>rostata-<u>s</u>pezifisches <u>M</u>embran<u>a</u>ntigen
| |
| ;PSMA-I&T
| |
| : <u>PSMA</u>-<u>I</u>maging & <u>T</u>herapie
| |
| ;RA
| |
| : <u>R</u>heumatoiden <u>A</u>rthritis
| |
| ;RANKL
| |
| : <u>R</u>eceptor <u>a</u>ctivator of <u>n</u>uclear factor-<u>k</u>appaB <u>l</u>igand
| |
| ;rhTSH
| |
| : <u>R</u>ecombinant <u>h</u>uman <u>T</u>hyreoidea-<u>s</u>timulierendes <u>H</u>ormon
| |
| ;RI
| |
| : <u>R</u>adio<u>i</u>od
| |
| ;RIT
| |
| : <u>R</u>adio<u>i</u>od<u>t</u>herapie
| |
| ;RLT
| |
| : <u>R</u>adio<u>l</u>iganden<u>t</u>herapie
| |
| ;RSO
| |
| : <u>R</u>adio<u>s</u>ynovi<u>o</u>rthese
| |
| ;SIRT
| |
| : <u>S</u>elektive <u>I</u>nterne <u>R</u>adio<u>t</u>herapie
| |
| ;[[StrlSchG]]
| |
| : {{#lst:StrlSchG|abk}}
| |
| ;[[StrlSchV]]
| |
| : {{#lst:StrlSchV|abk}}
| |
| ;TARE
| |
| : <u>T</u>rans<u>a</u>rterielle <u>R</u>adio<u>e</u>mbolisation
| |
| ;TSH
| |
| : <u>T</u>hyreoidea-<u>s</u>timulierendes <u>H</u>ormon - Thyreotropin
| |
| ;ULN
| |
| : <u>U</u>pper <u>L</u>imit of <u>N</u>ormal (''Obere Normgrenze'')
| |
| ;[[WHO]]
| |
| : {{#lst:WHO|abk}}
| |
| ;Zevalin
| |
| : Ibritumomab-Tiuxetan
| |
|
| |
|
| |
|
| |
|
| |
|
| __HIDDENCAT__ | | __HIDDENCAT__ |
| [[Category:AG83]] | | [[Category:AG83]] |
Begriffe die in der 6. Sitzung der AG83 am geprüft werden.
Begriffe aus der A630
